Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. (Q38901804)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

review article

1 reference

title

Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

main subject

cognitive dysfunction

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Philip E Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Mary C Tierney

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Wei Wu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Kathleen I Pritchard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

English

0 references

publication date

18 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

19 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

407-420

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27432418%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-016-3906-9

19 March 2020

exact match

0 references

cites work

Breast cancer statistics, 2013.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

HER2 status in elderly women with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Aromatase inhibitors and mental function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

The use of estrogen in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Incidence of dementia among participants and nonparticipants in a longitudinal study of cognitive aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Breast cancer: current and future endocrine therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Aromatase inhibitors for breast cancer: lessons from the laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

The effects of hormone therapy on cognition in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Decision-making impairments in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Analysis of memory deficits following chemotherapy in breast cancer survivors: evidence from the doors and people test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Effects of adjuvant treatment on cognitive function in women with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive impairment associated with adjuvant therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Estrogen- and tamoxifen-associated effects on brain structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive function in breast cancer patients prior to adjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive function and breast cancer: promise and potential insights from functional brain imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9

Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3906-9